Piper Sandler Maintains Overweight Rating on ImmunityBio Amid Pipeline Advancement

Piper Sandler has maintained its overweight rating on ImmunityBio, Inc. (IBRX), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and infectious diseases. The firm highlighted the company’s advancing pipeline, including Phase 2 trials for its T-cell engaging platform in solid tumors and ongoing development of a next-generation vaccine for respiratory syncytial virus (RSV). These initiatives are central to ImmunityBio’s strategy to expand its addressable market in high-need therapeutic areas. The decision comes amid broader investor scrutiny of small-cap biotechs, where clinical milestones and funding dynamics heavily influence valuation. Despite ImmunityBio’s market capitalization of approximately $300 million as of March 2026, Piper Sandler emphasized the potential for near-term catalysts, including data readouts from its IBX-1125 program in combination with checkpoint inhibitors. The firm estimates a 30% probability of positive Phase 2 results by late 2026, which could trigger meaningful upside in the stock. Currently trading at $4.75 per share, IBRX has seen a 12% increase in the past 30 days, outperforming the broader healthcare sector. The overweight rating suggests analysts anticipate a potential total return of 25–35% over the next 12 months, contingent on successful trial outcomes and strategic partnerships. However, the stock remains highly volatile, with average daily trading volume below 500,000 shares, indicating limited liquidity. Market participants, particularly institutional investors focused on biotech growth, are monitoring ImmunityBio closely. The rating change has prompted modest interest from hedge funds, with several new positions reported in filings through early March. While the action is unlikely to move broader indices, it may influence sentiment among retail investors and specialty healthcare funds.